Great Lakes Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Great Lakes Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-148,815	Closed	-$10.3M	–	908
2024 Q1	$10.3M	Sell	148,815 -737	-0.5%	-$50.7K	0.09%	210
2023 Q4	$10.7M	Sell	149,552 -1,741	-1%	-$100K	0.1%	190
2023 Q3	$7.88M	Buy	+151,293	New	+$8.81M	0.07%	231

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Lakes Advisors's ITCI Position: Q2 2024 in Review

Great Lakes Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 148,815 shares — an estimated $10.3M sold.

Great Lakes Advisors first reported a position in ITCI in Q3 2023 and held it in 3 quarters. The position peaked at $10.7M in Q4 2023. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

Great Lakes Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
Great Lakes Advisors sold 148,815 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $10.3M.
Great Lakes Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 3 quarters.
Great Lakes Advisors's Intra-Cellular Therapies Inc. position peaked at $10.7M in Q4 2023.
376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Great Lakes Advisors's 13F filing for Q2 2024, filed 6 Aug 2024.